Venkatesh Kalyan

United Arab Emiratesbusiness executiveMale8.0Global Dominance: 0.00%

Venkatesh Kalyan is the General Manager of Novo Nordisk Gulf, a leading global healthcare company specializing in diabetes care and other chronic conditions. He has been instrumental in the introduction and promotion of innovative medical solutions in the region, emphasizing the importance of effective treatment options for patients. Recently, he was in the news for his comments on the approval of the weight management drug 'Wegovy' (semaglutide) by the Emirates Medicines Corporation, highlighting its benefits in reducing cardiovascular risks and supporting healthier lifestyles.